AstraZeneca Opts In To ROR Gamma T Inhibitor Space With Orca Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
BioMotiv spinout could realize up to $122.5 million under arrangement giving AstraZeneca global option rights to a late-stage preclinical program for producing drugs that regulate production of IL-17.
You may also be interested in...
Deal Watch: After Novartis Deal, GSK Increases Vaccine Emphasis With GlycoVaxyn Buyout
Sanofi moves into ROR gamma T R&D for potential autoimmune therapies in collaboration with Lead Pharma, while Intrexon acquires Belgium’s ActoGeniX and its platform technology for creating a novel class of biotherapeutics targeting the oral and GI tracts. Teva heads off dispute with Eagle, bringing in new bendamustine formulation.
Autoimmune RORγt Program May Portend Change Of Direction For Vitae
The drug-discovery specialist is mulling several potential partners for its ROR gamma t inhibitor program, which has potential in autoimmune indications. Two cash-generating deals with Boehringer Ingelheim have made the clinical-stage company self-sufficient for nearly a decade.
Health And Wellness Weekly Trademarks Review: 21 June
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.